A short drug course before surgery kept one bowel cancer from coming back
In the NEOPRISM-CRC trial at UCL and UCLH, 32 people with stage two or three bowel cancer of one specific genetic type were given up to nine weeks of the immunotherapy drug pembrolizumab before their operation, in place of the usual chemotherapy afterward 12.
Earlier results had 59% of patients showing no detectable disease after treatment and surgery. Now follow-up has reached 33 months, and none of the patients has had a recurrence. That includes the ones who still had small traces of cancer at surgery; in them, the leftover disease did not grow or spread 12. Under standard care, surgery followed by chemotherapy, about 25% of patients are expected to relapse within three years 12.